Insights

EU Joint Clinical Assessment (JCA): What US Biotechs Need to Know

The EU HTA Regulation introduces a mandatory Joint Clinical Assessment (...)

Early Access in Europe: Generating Revenue Before Marketing Authorisation

France, Italy, Germany and Switzerland all run early-access schemes that (...)

From Phase 2 Readout to a European Pricing Agreement: The 10 Gates

A decision-gated map of the European pathway for rare disease, (...)

Mirava Bio joins the Swiss Biotech Association

We are proud to announce that Mirava Bio is now (...)

Meet us at the World Orphan Drug Congress Europe 2025

Amsterdam | October 27–28 | Booth S19 Mirava Bio will (...)

Rethinking Market Entry for Rare-Disease Biotechs: How Mirava Bio is Redefining Go-to-Market in Europe, the Middle East, and Eurasia

By Vincent Lévêque, Co-Founder & CEO, Mirava Bio The Essence (...)